Nanoparticle?mediated siRNA delivery systems for cancer therapy

The small interfering RNA (siRNA)-based therapeutics have raised great attention since the first interference (RNAi)-derived drug, patisiran, was approved by US Food and Drug Administration, which represented a landmark in field of gene therapy. Given properties disease-associated expression, RNAi machinery is regarded as an essential factor for preparing precise medicine. However, over past few years, siRNA drugs are undergoing period clinical translation, major hurdle limited efficient delivery strategies. Therefore, this mini-review mainly focuses on describing state-of-the-art nanoscale platforms delivering payloads, also addressing their applications cancer Finally, status under trials discussed, providing comprehensive understanding oligonucleotide-mediated therapeutics.